Unlock the Editor’s Digest totally free
Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly e-newsletter.
Hovering gross sales of Eli Lilly’s vastly widespread diabetes and weight reduction medicine Mounjaro and Zepbound prompted the US pharmaceutical group to elevate its steerage for the 12 months and pushed its share worth in direction of file excessive territory.
The Indianapolis-based drugmaker now expects full-year income in a spread of $42.4bn to 43.6bn — a rise of $2bn at each ends in contrast with its earlier forecast — following a 26 per cent leap in first-quarter revenues and as additional manufacturing capability for the load loss medicine turns into accessible later this 12 months.
Investor hype over this new class of medication — generally known as GLP-1s — which analysts venture might generate greater than $100bn in annual gross sales by the top of the last decade, has propelled Eli Lilly’s market capitalisation above $700bn, making it the world’s largest pharmaceutical group by market worth.
Eli Lilly shares closed 6 per cent greater on Tuesday, taking its year-to-date achieve to 34 per cent. Shares of Denmark’s Novo Nordisk, which makes rival Ozempic and Wegovy medicines, are up greater than 29 per cent in 2024.
For its fiscal first quarter, Eli Lilly’s earnings per share got here in at $2.58, above analysts’ expectations of $2.47. However first-quarter revenues of $8.77bn fell barely beneath expectations due to an absence of manufacturing capability to satisfy the massive demand for GLP-1s.
Eli Lilly’s chief government David Ricks attributed the drugmaker’s efficiency to “robust gross sales of Mounjaro and Zepbound”, and stated the corporate was “quickly increasing manufacturing capability to make our incretin medicines accessible to extra sufferers”.
Eli Lilly final week introduced a deal to purchase a Wisconsin-based manufacturing facility for filling its injectable pens from Nexus Prescription drugs. The drugmaker has additionally now damaged floor on a brand new website in Germany. The Monetary Occasions additionally beforehand reported that Eli Lilly had tapped contract producers BSP Prescription drugs and Resilience to fill and end its pens.
Virtually all dose types of Mounjaro, which treats kind 2 diabetes, and Zepbound, which has been accepted for weight reduction, are briefly provide till the top of the second quarter of this 12 months, in accordance with a US Meals and Drug Administration database monitoring shortages.
Eli Lilly stated it “continues to develop manufacturing capability, with essentially the most important manufacturing will increase in 2024 anticipated within the second half of the 12 months”.
Gross sales in Eli Lilly’s new merchandise class rose by $1.79bn 12 months on 12 months to $2.39bn within the first quarter, pushed by Mounjaro and Zepbound. Gross sales of the latter totalled $517.4mn within the first quarter, 33 per forward of analyst expectations, although Mounjaro gross sales of $1.8bn lagged behind expectations.
Evan Seigerman, an analyst at BMO Capital Markets, stated in a word that “the vast majority of this miss was on account of an absence of provide, with Lilly seemingly shifting capability to Zepbound throughout . . . Q1”.